IL15 and hematologic disorder: Overall, our data revealed a heterogeneous spectrum of responses to BNT162b2 mRNA vaccination in patients with hematological malignancies who received cell therapies ranging from individuals unable to produce IFN-γ and IL-15 and unable to mount an Ab response to those whose innate and adaptive responses were similar to healthy individual.